Actinium Pharmaceuticals (ATNM) Stock Analysis: AI Score & Alternative Data
ATNM alt-data: web traffic climbing, sentiment lagging
Is Actinium Pharmaceuticals a buy right now? The alternative data says hold. This ATNM stock analysis is built on the 25+ alternative data signals AltIndex tracks on Actinium Pharmaceuticals every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 47/100: a Hold. The stock trades at $0.80 with a $25M market cap.
The bullish side of the 90-day ledger: web traffic up 21.7% to 8K monthly visits. The drag: sentiment down 18.0% to 82/100. That tension is what keeps the score mid-range.
ATNM’s broader alt-data profile also covers job postings (3 open roles), and headcount (58 employees, according to LinkedIn). Every signal links to its own page with full history, the ATNM technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on ATNM is just below.
Actinium Pharmaceuticals AI Stock Analysis
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of targeted therapies for patients with cancer.
Analysis generated July 31, 2026.
Recent Actinium Pharmaceuticals Stock Alerts
|
Actinium Pharmaceuticals | August 5 Price is down by -7.4% in the last 24h. |
|
Actinium Pharmaceuticals | July 8 Price is down by -6.7% in the last 24h. |
|
Actinium Pharmaceuticals | July 7 Price is up by 6.1% in the last 24h. |
|
Actinium Pharmaceuticals | June 25 Price is down by -6.3% in the last 24h. |
Actinium Pharmaceuticals Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 8K | 21.7% | |
| Job Posts | 3 | 0% | |
| LinkedIn Employees | 58 | N/A | |
| Employee Recommend | 0 | N/A | |
| Business Outlook | 0 | N/A | |
| Sentiment | 82 | 18.0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 7 | N/A | |
| Stocktwits Mentions | 108 | 44.0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 23K | 0.7% |
About Actinium Pharmaceuticals (ATNM)
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplantation (BMT) or a type of cell therapy, and for other adoptive cell therapies. The company is headquartered in New York, New York.
| Price | $0.80 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $25M |
| Year Range | $1 – $2 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Actinium Pharmaceuticals News
View more → |
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer ModelsJune 3 - PRNewswire |
 |
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 RadioconjugatesJune 1 - PRNewswire |
 |
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT ProgramsMay 29 - PRNewswire |
|
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards NoticeMay 29 - PRNewswire |
 |
Hematopoietic Stem Cell Transplantation Market Landscape to Evolve at a CAGR of 12.4% During the Forecast Period (2026-2036) as Novel Therapies and Expanding Patient Eligibility Drive Growth | DelveInsightJune 22 - PRNewswire |
Actinium Pharmaceuticals Earnings & Financial Performance
View all earnings →Actinium Pharmaceuticals Insider Trading Activity
View all →| No recent insider transactions on file. |
Actinium Pharmaceuticals Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Actinium Pharmaceuticals
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
LongeveronLGVN |
$0.77 1.0% | $24M | 50 |
 |
Atossa TherapeuticsATOS |
$2.36 2.5% | $24M | 48 |
 |
Actuate TherapeuticsACTU |
$1.11 10.2% | $26M | 0 |
 |
Tevogen Bio HoldingsTVGN |
$6.47 0.2% | $27M | 44 |
 |
Allarity TherapeuticsALLR |
$1.39 0.7% | $22M | 50 |
Explore Actinium Pharmaceuticals Data
Frequently Asked Questions: Actinium Pharmaceuticals (ATNM)
Actinium Pharmaceuticals has an AltIndex AI Score of 47/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
47/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Actinium Pharmaceuticals (ATNM) stock is $0.80 with a market cap of $25M.
As of today, Actinium Pharmaceuticals’s PE (Price to Earnings) ratio is —.
View the latest Actinium Pharmaceuticals insider transactions to see recent buying and selling activity by company executives and directors.
Check the Actinium Pharmaceuticals congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The ATNM stock price chart above shows Actinium Pharmaceuticals’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Actinium Pharmaceuticals technical analysis for RSI, moving averages, and more.
See the stocks similar to Actinium Pharmaceuticals section on this page for companies in the same industry ranked by market cap and AI Score.
